Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ProPhase Labs (PRPH) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for ProPhase Labs (PRPH) over the last 16 years, with Q3 2025 value amounting to 774.75%.

  • ProPhase Labs' EBITDA Margin fell 3096300.0% to 774.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 820.16%, marking a year-over-year decrease of 51730300.0%. This contributed to the annual value of 783.26% for FY2024, which is 7323000.0% down from last year.
  • According to the latest figures from Q3 2025, ProPhase Labs' EBITDA Margin is 774.75%, which was down 3096300.0% from 358.46% recorded in Q2 2025.
  • In the past 5 years, ProPhase Labs' EBITDA Margin ranged from a high of 277.15% in Q1 2025 and a low of 2254.59% during Q4 2024
  • Over the past 5 years, ProPhase Labs' median EBITDA Margin value was 15.99% (recorded in 2021), while the average stood at 221.39%.
  • In the last 5 years, ProPhase Labs' EBITDA Margin plummeted by -23838500bps in 2024 and then surged by 5362700bps in 2025.
  • ProPhase Labs' EBITDA Margin (Quarter) stood at 23.33% in 2021, then plummeted by -127bps to 6.42% in 2022, then soared by 2115bps to 129.26% in 2023, then plummeted by -1844bps to 2254.59% in 2024, then skyrocketed by 66bps to 774.75% in 2025.
  • Its last three reported values are 774.75% in Q3 2025, 358.46% for Q2 2025, and 277.15% during Q1 2025.